Recent studies indicate the inversely proportional relationship of adiponectin concentration in the blood and metabolic syndrome as well as its anti-inflammatory and anti-atherogenic potential in the treatment of metabolic syndrome and type 2 diabetes (27, 28). The gene discussed is ADIPOQ; the disease is type 2 diabetes mellitus.